Clinical trials: Buprenorphine
Opioid-Related Disorders
Gradual Vs. Rapid Buprenorphine Detoxification - 2
The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.
- Trial name
- NCT00000220
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Opioid Withdrawal
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
There are more than 2.1 million people in the United States with opioid use disorder, and according to preliminary data from the US Centers for Disease Control and Prevention opioid overdose deaths rose 36% to more than 69,000…
- Trial name
- NCT05307458
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- United Health Services Hospitals, Inc.
Hepatitis C, Chronic, Substance Abuse Treatment Centers
Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine.
- Conditions
- Hepatitis C, Chronic, Substance Abuse Treatment Centers, Opioid-Related Disorders
- Trial name
- HepCOP (NCT00473993)
- Sponsor
- Seidenberg, Arztpraxis A., M.D.
Osteoarthritis, Rheumatoid Arthritis
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT01961271
- Testing
- Buprenorphine transdermal patch
- Where
- 16 sites in Hong Kong, Philippines and 1 more
- Volunteers
- 114 people
- Sponsor
- Mundipharma Pte Ltd.
Healthy Volunteers
Effects of Buprenorphine on Ulnar Nerve Motor Block
Recent reports showed that the opioid buprenorphine is a very potent sodium channel blocker. Buprenorphine not only exerts a strong antinociception, but also a long lasting antihyperalgesic effect.
- Trial name
- NCT00949299
- Testing
- buprenorphine
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Obesity, Morbid
Bariatric Surgery and Pharmacokinetics of Buprenorphine
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines.
- Trial name
- NCT03460314
- Testing
- Buprenorphine
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Norwegian University of Science and Technology
Opioid Use Disorder, Chronic Pain
Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management
The investigators plan to develop and pilot test an integrated, web-based cognitive behavioral approach and then conduct a randomized clinical trial evaluating its efficacy relative to standard care in a large and diverse sample…
- Trial name
- IMPACT (NCT05204576)
- Testing
- CBT4CBT COPES
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Yale University
Opioid Use Disorder, Opioid-related Disorders
Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder
A multi-center, open-label, long-term safety study in which approximately 600 subjects diagnosed with opioid use disorder will be enrolled.
- Trial name
- NCT02510014
- Testing
- SUBOXONE sublingual film, RBP-6000
- Where
- 42 sites in United States
- Volunteers
- 775 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder
Single Ascending Dose Study of RBP-6000
A multi-center, open-label, single ascending dose study to enroll opioid dependent treatment-seeking subjects. Subjects to be enrolled into 3 cohorts receiving low, medium and high doses of depot buprenorphine.
- Trial name
- SAD (NCT03002961)
- Testing
- RBP-6000, Suboxone
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Indivior Inc.
Opioid-use Disorder
Medication Maintenance Therapy in Community Pharmacy Settings
The goal of this study is to examine how the pharmacy can better optimize treatment expansion by providing pharmacy-based medication assisted treatment (MAT) for maintenance under a collaborative pharmacy practice agreement.
- Trial name
- MATPharm (NCT03766893)
- Testing
- Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Lifespan
Chronic Pain, Opioid Pain Medication
Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper
Chronic opioid therapy for pain can be associated with significant risks, and a significant number of patients maintained on chronic opioids have continued pain and/or poor functioning.
- Trial name
- NCT02737826
- Testing
- Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Buprenorphine taper - Phase II
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical University of South Carolina
Opioid-Related Disorders
Alternate-Day Buprenorphine Administration. Phase VII - 8
The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.
- Trial name
- NCT00000226
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Maternal Opioid Use Disorder, Opioid Exposed Infant
Maternal Buprenorphine-naloxone Treatment and the Infant
The purpose of this mechanistic study is to evaluate the effects that maternal buprenorphine-naloxone maintenance have on the neurobehavioral development of the fetus and infant.
- Trial name
- NCT03291847
- Testing
- fetal monitoring, Buprenorphine Naloxone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Johns Hopkins University
Osteoarthritis, Pain
Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine
The primary objective of this equivalence study is to evaluate the efficacy of Norspan® patches versus Tramadol in subjects with chronic, moderate to severe osteoarthritis pain of the hip, knee and/or lumbar spine.
- Trial name
- NCT00426647
- Testing
- Buprenorphine, Tramadol
- Where
- Finland
- Volunteers
- 120 people
- Sponsor
- Norpharma A/S
Chronic Pain
Virtual Pain Care Management (COVID-19)
The COVID-19 pandemic is exacerbating the challenges faced by Veterans at risk of opioid overdose including Veterans prescribed moderate-to-high dose long-term opioid therapy (LTOT) whose usual treatment resources and coping…
- Trial name
- VCPM (NCT04539821)
- Testing
- VCPM
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Opiate Suicide Study in Patients With Major Depression
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately…
- Trial name
- AFSP (NCT04116528)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Opioid-Related Disorders
Buprenorphine Group Medical Visits in Primary Care
The primary goal of this research is to improve the effectiveness of buprenorphine maintenance treatment (BMT) within primary care.
- Trial name
- G-BMT (NCT02526212)
- Testing
- G-BMT, Treatment as usual, Buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Montefiore Medical Center
Opioid Use Disorder
Olanzapine in OUD Patients
This study is designed to examine whether olanzapine (2.5 to 20mg/day) impacts opioid use in patients with opioid use disorder and comorbid SMI symptoms who are taking buprenorphine-naloxone.
- Trial name
- NCT05179772
- Testing
- Olanzapine
- Where
- 2 sites in United States
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD
This is a multicenter, randomized, double-blind, placebo-controlled, parallel, multiple dose study designed to evaluate the safety and tolerability of the co-formulation of ALKS 33 with buprenorphine (ALKS 5461) in subjects with…
- Trial name
- NCT01381107
- Testing
- ALKS 5461
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Alkermes, Inc.
Opiate-related Disorders, Opiate Dependence
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
This study is designed to determine if opioid dependent subjects who are already receiving Subutex® prefer the Suboxone® tablet over the Subutex® tablet after switching from Subutex® to Suboxone®.
- Conditions
- Opiate-related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00684073
- Testing
- buprenorphine, buprenorphine/naloxone
- Volunteers
- 60 people
- Sponsor
- Indivior Inc.